$0.89
-0.01 (-1.12%)
Open$0.89
Previous Close$0.90
Day High$0.90
Day Low$0.87
52W High$1.85
52W Low$0.45
Volume—
Avg Volume253.2K
Market Cap143.64M
P/E Ratio—
EPS$-0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,168.8% upside
Current
$0.89
$0.89
Target
$20.19
$20.19
$14.44
$20.19 avg
$28.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.90M | 15.53M | 15.53M |
| Net Income | 2.54M | 3.35M | 2.88M |
| Profit Margin | 17.0% | 21.6% | 18.5% |
| EBITDA | 5.18M | 5.39M | 5.26M |
| Free Cash Flow | 2.62M | 3.23M | 2.70M |
| Rev Growth | -8.5% | -1.6% | +3.5% |
| Debt/Equity | 0.17 | 0.17 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |